Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Novocure announced MHLW approval of Optune Pax for unresectable locally advanced pancreatic cancer, to be used with gemcitabine and nab—paclitaxel.Key Highlights:Original SEC Filing: NovoCure Ltd [ NVCR ] - 8-K - Oct. 01, 2026This is an AI-powered summary. It may contain inaccuracies. Consider veri…
Novocure's Optune Pax has received approval from Japan's MHLW for adult patients with unresectable locally advanced pancreatic cancer. The approval is for use in combination with gemcitabine and nab-paclitaxel, following positive results from the Phase 3 PANOVA-3 trial which demonstrated improved median overall surviva
Novocure announced that Japan's Ministry of Health, Labour and Welfare approved Optune Pax for adult patients with unresectable locally advanced pancreatic cancer, when used concomitantly with gemcitabine and nab-paclitaxel.
NovoCure (NASDAQ: NVCR ) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. The full earnings call is available at Summary NovoCure rep